

Freedom of Information Act 2000 – Request Reference FoI/24/214
Dermatological Conditions

The below information reflects the period 1 December 2023 to 31 March 2024.

Question 1. How many patients were treated in the last 4 months (December 2023 to March 2024) by the dermatology department with each of the following products:

Abrocitinib – 4
Acitretin – 119
Alitretinoin – 14
Azathioprine – 2
Baricitinib – 9
Ciclosporin – 9
Dupilumab – 86
Lebrikizumab – 0
Methotrexate – 12
Mycophenolate mofetil – 1
Pimecrolimus – 1
Phototherapy (UVB or PUVA) – for Atopic Dermatitis only – 42 for UVB with atopic dermatitis and 8 for UVA with atopic dermatitis
Tacrolimus ointment – 19
Tralokinumab – 2
Upadacitinib – 14

Question 2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

Of the patients above, with the exception of Phototherapy:

Patients aged 6–11 – 3
Patients aged 12–17 – 16
Patients aged 18 and above – 260

For Phototherapy only:

All 8 UVA patients were aged 18 and above.

UVB patients aged 6–11 – 10
UVB patients aged 12–17 – 11
UVB patients aged 18 and above – 21